|
molecular tumour board |
10 |
|
next-generation sequencing |
10 |
|
precision oncology |
10 |
|
sequence-directed therapy |
10 |
|
bintrafusp alfa |
8 |
|
correlative biomarkers |
8 |
|
efficacy |
8 |
|
recurrent or metastatic nasopharyngeal cancer |
8 |
|
safety |
8 |
|
cancer-associated venous thrombosis (cat) |
7 |
|
cost-effectiveness |
7 |
|
direct oral anticoagulants (doacs) |
7 |
|
low-molecular-weight heparin (lmwh) |
7 |
|
markov state-transition model |
7 |
|
quality-adjusted life years (qalys) |
7 |
|
breast cancer |
4 |
|
competing risk analysis |
3 |
|
country income |
3 |
|
deep learning |
3 |
|
disparity |
3 |
|
epidemiology |
3 |
|
fibers |
3 |
|
low-dose volume |
3 |
|
lymphopenia |
3 |
|
radiotherapy (rt) |
3 |
|
second primary cancer |
3 |
|
seer |
3 |
|
sodium |
3 |
|
trend |
3 |
|
whole grains |
3 |
|
advanced gastric adenocarcinoma |
2 |
|
immune checkpoint inhibition (ici) |
2 |
|
microsatellite instability (msi) |
2 |
|
pd-l1 |
2 |
|
tumor mutational burden (tmb) |
2 |
|
adenosine triphosphate (atp) |
1 |
|
colorectal cancer |
1 |
|
drug combination |
1 |
|
hormone therapy |
1 |
|
mapk |
1 |
|
metastasis-associated antigen 1 (mta1) |
1 |
|
methylthioadenosine phosphorylase |
1 |
|
mitochondrial glucose metabolism |
1 |
|
mtap |
1 |
|
mtor inhibitors |
1 |
|
non-small-cell lung cancer |
1 |
|
ovarian cancer |
1 |
|
pancreas cancer |
1 |
|
prmt5 |
1 |
|
protein arginine methyltransferase 5, synthetic lethality |
1 |
|
qol |
1 |
|
quality of life |
1 |
|
resistance |
1 |
|
src |
1 |
|
survival |
1 |
